Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Zinaida Yu. Mutovina"'
Autor:
Sergey N. Avdeev, Vladimir P. Chulanov, Ekaterina I. Alexeeva, Olga A. Aleshina, Aleksey V. Bereznikov, Oleg N. Kotenko, Aleksander M. Lila, Zinaida Yu. Mutovina, Elena N. Parovichnikova, Daria S. Fomina, Nadiya F. Frolova, Alexey O. Shevchenko
Publikováno v:
Терапевтический архив, Vol 95, Iss 8, Pp 722-729 (2023)
On July 3, 2023, an interdisciplinary Council of Experts The burden of COVID-19 in a heterogeneous population of immunocompromised patients post-pandemic realities was held in Moscow with leading experts in pulmonology, rheumatology, hematology, onco
Externí odkaz:
https://doaj.org/article/87994ce57ab2448b9f97ce142a57085f
Autor:
Ulyana A. Markina, Daria S. Fomina, Marina S. Lebedkina, Tatiana S. Kruglova, Anton A. Chernov, Alena I. Zagrebneva, Zinaida Yu. Mutovina, Alexander V. Karaulov, Ekaterina I. Alexeeva, Mariana A. Lysenko
Publikováno v:
Терапевтический архив, Vol 94, Iss 5, Pp 675-682 (2022)
Background. The use of virus-neutralizing monoclonal antibodies is an effective method of etiotropic therapy for SARS-CoV-2 in patients of high-risk groups of severe COVID-19. Regdanvimab is a single-component monoclonal antibodies immunoglobulin G1,
Externí odkaz:
https://doaj.org/article/1ca7266523cb42cb8962e01de2e8c208
Autor:
Tatyana S. Kruglova, Darya S. Fomina, Nataliya G. Poteshkina, Nadija F. Frolova, Irina P. Beloglazova, Zinaida Yu. Mutovina, Inna V. Samsonova, Elena A. Kovalevskaja, Alena I. Zagrebneva, Sofya A. Serdotetckova, Anton A. Chernov, Maryana A. Lysenko
Publikováno v:
Терапевтический архив, Vol 93, Iss 11, Pp 1316-1324 (2021)
Aim. To determine the criteria for the optimal use of IL-6 receptor blockers in patients with COVID-19 community-acquired pneumonia based on predictors of adverse outcomes. Materials and methods. The single-center, non-randomized prospective study
Externí odkaz:
https://doaj.org/article/6b1c4220c5664b0daa936e831f62deb9
Autor:
Daria Fomina, Mar’yana A. Lysenko, Irina P. Beloglazova, Zinaida Yu. Mutovina, Nataliya G. Poteshkina, Inna V. Samsonova, Tat’yana S. Kruglova, Anton A. Chernov, Alexander V. Karaulov
Publikováno v:
Pathogens and Immunity, Vol 5, Iss 1, Pp 327-341 (2020)
Background: Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm. Methods: We treated 89 hospitalized patients with COVID-19 pneumonia and
Externí odkaz:
https://doaj.org/article/693405732e0746a78a68eff75b427535
Autor:
Alexander Karaulov, Anton A. Chernov, Inna V. Samsonova, Irina P. Beloglazova, Daria Fomina, M. A. Lysenko, Zinaida Yu. Mutovina, Nataliya G. Poteshkina, Tat'yana S. Kruglova
Publikováno v:
Pathogens and Immunity
Pathogens and Immunity, Vol 5, Iss 1, Pp 327-341 (2020)
Pathogens and Immunity, Vol 5, Iss 1, Pp 327-341 (2020)
Background: Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm.Methods: We treated 89 hospitalized patients with COVID-19 pneumonia and h
Autor:
Irina P. Beloglazova, Elena A. Kovalevskaуa, Inna V. Samsonova, M. A. Lysenko, Anton A. Chernov, Sof'ya A. Serdotetckova, Elena N. Bobrikova, Zinaida Yu. Mutovina, Dar'ya S. Fomina, Nadija F. Frolova, N. G. Poteshkina, Tat'yana N. Markova, Dar'ya B. Krlykova, Alena I. Zagrebneva, Tat'yana S. Kruglova, Oksana V. Manchenko
Publikováno v:
Russian Pulmonology. 30:164-172
According to accumulated clinical data, one of the causes of severe damage to lung epithelial cells associated with SARS-CoV-2 (2019-nCoV) is an acute, timely underestimated "cytokine storm" (cytokine cascade, hypercytokinaemia) with characteristic s
Autor:
Tatyana S. Kruglova, Darya S. Fomina, Nataliya G. Poteshkina, Nadija F. Frolova, Irina P. Beloglazova, Zinaida Yu. Mutovina, Inna V. Samsonova, Elena A. Kovalevskaja, Alena I. Zagrebneva, Sofya A. Serdotetckova, Anton A. Chernov, Maryana A. Lysenko
Publikováno v:
Терапевтический архив, Vol 93, Iss 11, Pp 1316-1324 (2021)
To determine the criteria for the optimal use of IL-6 receptor blockers in patients with COVID-19 community-acquired pneumonia based on predictors of adverse outcomes.The single-center, non-randomized prospective study included 190 patients with comm
Autor:
Inna V. Samsonova, Alexander Karaulov, Daria Fomina, Michael M. Lederman, Anton A. Chernov, Zinaida Yu. Mutovina, Irina P. Beloglazova, Nataliya G. Poteshkina, M. A. Lysenko, Tat'yana S. Kruglova
BackgroundEmerging evidence links morbidity and mortality of pandemic COVID-19 pneumonia to an inflammatory cytokine storm.MethodsEighty nine patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C reactive protein and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6635535b2dc460646028a266c8c6471